These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 36476380)

  • 1. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
    Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
    Qu P; Evans JP; Faraone J; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    bioRxiv; 2022 Oct; ():. PubMed ID: 36299423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1.
    Wang J; Shi B; Chen H; Yu M; Wang P; Qian Z; Hu K; Wang J
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant.
    Khan K; Lustig G; Römer C; Reedoy K; Jule Z; Karim F; Ganga Y; Bernstein M; Baig Z; Jackson L; Mahlangu B; Mnguni A; Nzimande A; Stock N; Kekana D; Ntozini B; van Deventer C; Marshall T; Manickchund N; Gosnell BI; Lessells RJ; Karim QA; Abdool Karim SS; Moosa MS; de Oliveira T; von Gottberg A; Wolter N; Neher RA; Sigal A
    Nat Commun; 2023 Dec; 14(1):8078. PubMed ID: 38057313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective clinical performance of CoVarScan in identifying SARS-CoV-2 Omicron subvariants.
    Zhu K; Sah M; Mahimainathan L; Liu Y; Xing C; Roush K; Clark A; SoRelle J
    Microbiol Spectr; 2024 Dec; ():e0138524. PubMed ID: 39660915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benchmark Investigation of SARS-CoV-2 Mutants' Immune Escape with 2B04 Murine Antibody: A Step Towards Unraveling a Larger Picture.
    Kapusta K; McGowan A; Banerjee S; Wang J; Kolodziejczyk W; Leszczynski J
    Curr Issues Mol Biol; 2024 Nov; 46(11):12550-12573. PubMed ID: 39590339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant.
    Qu P; Evans JP; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2022 Nov; 30(11):1518-1526.e4. PubMed ID: 36240764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    Jia T; Wang F; Chen Y; Liao G; Xu Q; Chen J; Wu J; Li N; Wang L; Yuan L; Wang D; Xie Q; Luo C; Luo H; Wang Y; Chen Y; Shu Y
    J Infect; 2024 Dec; 89(6):106362. PubMed ID: 39608577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.
    Feng Y; Yuan M; Powers JM; Hu M; Munt JE; Arunachalam PS; Leist SR; Bellusci L; Kim J; Sprouse KR; Adams LE; Sundaramurthy S; Zhu X; Shirreff LM; Mallory ML; Scobey TD; Moreno A; O'Hagan DT; Kleanthous H; Villinger FJ; Veesler D; King NP; Suthar MS; Khurana S; Baric RS; Wilson IA; Pulendran B
    Sci Transl Med; 2023 May; 15(695):eadg7404. PubMed ID: 37163615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.
    Wang Q; Guo Y; Schwanz LT; Mellis IA; Sun Y; Qu Y; Urtecho G; Valdez R; Stoneman E; Gordon A; Wang HH; Ho DD; Liu L
    Emerg Microbes Infect; 2024 Dec; 13(1):2359004. PubMed ID: 38779718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains.
    Starr TN; Greaney AJ; Stewart CM; Walls AC; Hannon WW; Veesler D; Bloom JD
    PLoS Pathog; 2022 Nov; 18(11):e1010951. PubMed ID: 36399443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape.
    Raisinghani N; Alshahrani M; Gupta G; Verkhivker G
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case.
    Kuwata T; Kaku Y; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Uraki R; Okazaki K; Minami R; Nagasaki Y; Nagashima M; Yoshida I; Sadamasu K; Yoshimura K; Ito M; Kiso M; Yamayoshi S; Imai M; Ikeda T; Sato K; Toyoda M; Ueno T; Inoue T; Tanaka Y; Kimura KT; Hashiguchi T; Sugita Y; Noda T; Morioka H; Kawaoka Y; Matsushita S;
    EBioMedicine; 2024 Dec; 110():105439. PubMed ID: 39488016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2.
    Wang Q; Li Z; Guo Y; Mellis IA; Iketani S; Liu M; Yu J; Valdez R; Lauring AS; Sheng Z; Gordon A; Liu L; Ho DD
    iScience; 2023 Nov; 26(11):108254. PubMed ID: 38026207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
    Meng B; Abdullahi A; Ferreira IATM; Goonawardane N; Saito A; Kimura I; Yamasoba D; Gerber PP; Fatihi S; Rathore S; Zepeda SK; Papa G; Kemp SA; Ikeda T; Toyoda M; Tan TS; Kuramochi J; Mitsunaga S; Ueno T; Shirakawa K; Takaori-Kondo A; Brevini T; Mallery DL; Charles OJ; ; ; ; Bowen JE; Joshi A; Walls AC; Jackson L; Martin D; Smith KGC; Bradley J; Briggs JAG; Choi J; Madissoon E; Meyer KB; Mlcochova P; Ceron-Gutierrez L; Doffinger R; Teichmann SA; Fisher AJ; Pizzuto MS; de Marco A; Corti D; Hosmillo M; Lee JH; James LC; Thukral L; Veesler D; Sigal A; Sampaziotis F; Goodfellow IG; Matheson NJ; Sato K; Gupta RK
    Nature; 2022 Mar; 603(7902):706-714. PubMed ID: 35104837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of a monoclonal antibody targeting the SARS-CoV-2 Omicron spike protein and analysis of SARS-CoV-2 Omicron mutations related to monoclonal antibody resistance.
    Kim J; Kim S; Park S; Kim D; Kim M; Baek K; Kang BM; Shin HE; Lee MH; Lee Y; Kwon HJ
    Microbes Infect; 2024 Nov; ():105461. PubMed ID: 39580070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.
    Patel V; Levick B; Boult S; Gibbons DC; Drysdale M; Lloyd EJ; Singh M; Birch HJ
    BMC Infect Dis; 2024 Apr; 24(1):428. PubMed ID: 38649824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antibody from single human V
    Luo S; Zhang J; Kreutzberger AJB; Eaton A; Edwards RJ; Jing C; Dai HQ; Sempowski GD; Cronin K; Parks R; Ye AY; Mansouri K; Barr M; Pishesha N; Williams AC; Vieira Francisco L; Saminathan A; Peng H; Batra H; Bellusci L; Khurana S; Alam SM; Montefiori DC; Saunders KO; Tian M; Ploegh H; Kirchhausen T; Chen B; Haynes BF; Alt FW
    Sci Immunol; 2022 Oct; 7(76):eadd5446. PubMed ID: 35951767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.